GlassScriptPhysician profile
Manuel Zevallos
NPI 1174611750
$30,044.71
in general payments reported to CMS, 2019-2025
88 companies · $4,295 in 2025
The $4,295 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,228 · 2020: $3,125 · 2021: $2,676 · 2022: $4,993 · 2023: $5,299 · 2024: $4,429 · 2025: $4,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,330.49 |
| Education | $693.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,675.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,548.00 | 2019-2025 | |
| Pfizer INC. | $1,659.69 | 2019-2025 | |
| Incyte Corporation | $1,597.72 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $1,591.06 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,467.69 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $1,442.08 | 2019-2025 | Opdivo, Opdualag |
| Eisai INC. | $1,117.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,092.88 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $998.29 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Janssen Biotech, INC. | $968.08 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $926.92 | 2019-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Exelixis INC. | $874.97 | 2020-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $587.71 | 2020-2025 | |
| Genentech USA, INC. | $584.20 | 2019-2025 | Phesgo, Tecentriq, Polivy |
Show all 88 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Zevallos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.